Benign prostate hyperplasia: A review of the year's progress from bench to clinic

Current Opinion in Urology

Volumn 21, Issue 1, 2011, Pages 22-26

  Donnell, Robert F ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

benign prostate hyperplasia; inflammation; lower urinary tract symptoms; medical therapy; metabolic syndrome; surgical therapies

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN RECEPTOR; BOTULINUM TOXIN A; DUTASTERIDE; EVIPROSTAT; NAFTOPIDIL; PLACEBO; SILDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; VITAMIN D RECEPTOR;

ARTICLE; CELL COMMUNICATION; DRUG MECHANISM; GENETICS; HUMAN; INFLAMMATION; LIFESTYLE; LOWER URINARY TRACT SYMPTOM; METABOLIC SYNDROME X; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROSTATECTOMY;

HUMANS; INFLAMMATION; MALE; METABOLIC SYNDROME X; PROSTATIC HYPERPLASIA; UROLOGIC DISEASES;

EID: 78650483392     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32834100dd     Document Type: Article

References (32)

1. Ford ES, Giles WH, Dietz WH. Prevelance of metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287:356-359.
2. PhillipsGB. Sex hormones, risk factors and cardiovascular disease. Am J Med 1978; 65:7-11.
3. Vikram A, Jena GB, Ramarao P. Increased cell proliferation and contractility of prostate in insulin resistant rats: Linking hyperinsulinemia with benign prostate hyperplasia. Prostate 2010; 70:79-89. The article investigates the relationship between elements of the metabolic syndrome and clinically significant BPH. It is particularly important for urology to understand the metabolic syndrome and its implications to health in a period when the features of the metabolic syndrome have become the number one health issue in the USA.
4. Sea J, Poon KS, McVary KT. Review of exercise and the risk of benign prostatic hyperplasia. Phys Sportsmed 2009; 37:75-83.
5. Kohnen PW, Drach GW. Patterns of inflammation in prostatic hyperplasia: A histologic and bacteriologic study. J Urol 1979; 121:755-760.
6. Di Silverio F, Gentile V, De Matteis A, et al. Distribution of inflammation, premalignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia, a retrospective analysis. Eur Urol 2003; 43:164-175.
7. Roehrborn C, Kaplan SA, Noble WD, et al. The impact of acute and chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: Results of the MTOP study. J Urol 2005; 173:204.
8. Schenk JM, Kristal AR, Neuhouser ML, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial. Am J Epidemiol 2010; 171:571-582.
9. Kristal AR, Price DK, Till C, et al. Androgen receptor CAG repeat length is not associated with the risk of incident symptomatic benign prostatic hyperplasia: Results from the Prostate Cancer Prevention Trial. Prostate 2010; 70:584-590.
10. O'Malley KJ, Dhir R, Nelson JB, et al. The expression of androgen-responsive genes is up-regulated in the epithelia of benign prostatic hyperplasia. Prostate 2009; 69:1716-1723.
11. Yang X, Xuan Q, Mo L, et al. Differential expression of genes in co-cultured versus separately cultured fibroblasts and epithelial cells from human benign hyperplastic prostate tissues. Int J Mol Med 2010; 26:17-25.
12. Park II, Zhang Q, Liu V, et al. 17Beta-estradiol at low concentrations acts through distinct pathways in normal versus benign prostatic hyperplasiaderived prostate stromal cells. Endocrinology 2009; 150:4594-4605.
13. Lee YC, Wu WJ, Liu CC, et al. The associations among eNOS G894T gene polymorphism, erectile dysfunction, and benign prostate hyperplasia-related lower urinary tract symptoms. J Sex Med 2009; 6:3158-3165. Genetic differences between men who develop significant LUTS due to BPH and men without symptoms offer a potentially interesting target for therapy, but also offers an interval opportunity to chose who may benefit from more aggressive therapies to prevent progression while excluding those men who would be less likely to benefit from this class of drugs.
14. Fibbi B, Morelli A, Vignozzi L, et al. Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 2010; 7 (1 Pt 1):59-69. Increased understanding of the PDE-5 distribution/activity in the bladder and the prostate are an important beginning for additional research. The initial clinical studies of PDE-5 inhibitors have been associated with greater improvement in symptom score than in the objective parameters but the studies are short duration. The role of PDE-5 inhibitors in endothelial health and thus prevention of disease make this an important paper.
15. Porst H, McVary KT, Montorsi F, et al. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009; 56:727-735.
16. Tuncel A, Nalcacioglu V, Ener K, et al. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol 2010; 28:17-22.
17. Adorini L, Penna G, Fibbi B, Maggi M. Vitamin D receptor agonists target static, dynamic, and inflammatory components of benign prostatic hyperplasia. Ann N Y Acad Sci 2010; 1193:146-152.
18. Oka M, Ueda M, Oyama T, et al. Effect of the phytotherapeutic agent eviprostat on 17beta-estradiol-induced nonbacterial inflammation in the rat prostate. Prostate 2009; 69:1404-1410.
19. Tagaya M, Oka M, Ueda M, et al. Eviprostat suppresses proinflammatory gene expression in the prostate of rats with partial bladder-outlet obstruction: A genome-wide DNA microarray analysis. Cytokine 2009; 47:185-193.
20. Kawachi Y, Sakurai T, Sugimura S, et al. Long-term treatment and prognostic factors of alpha 1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: A pilot study comparing naftopidil and tamsulosin hydrochloride. Scand J Urol Nephrol 2010; 44:38-45.
21. Van Gils MP, Hessels D, Peelen WP, et al. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: A randomized, openlabel, parallel-group pilot study. Prostate 2009; 69:1624-1634.
22. Roehrborn CG, Siami P, Barkin J, et al.,COMBAT Study Group. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the COMBAT study. Eur Urol 2010; 57:123-131.
23. Kojima Y, Sasaki S, Oda N, et al. Prostate growth inhibition by subtypeselective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia. Prostate 2009; 69:1521-1528.
24. Doggweiler R, Zermann DH, Ishigooka M, Schmidt RA. Botox-induced prostatic involution. Prostate 1998; 37:44-50.
25. Silva J, Pinto R, Carvallho T, et al. Mechanisms of prostate atrophy after glandular botulinum neurotoxin type a injection: An experimental study in the rat. Eur Urol 2009; 56:134-140.
26. Chen Q, Zhang L, Liu YJ, et al. Bipolar transurethral resection in saline system versus traditional monopolar resection system in treating large-volume benign prostatic hyperplasia. Urol Int 2009; 83:55-59.
27. Yun HK, Kwon JB, Cho SR, Kim JS. Early experience with laparoscopic retropubic simple prostatectomy in patients with voluminous benign prostatic hyperplasia (BPH). Korean J Urol 2010; 51:323-329.
28. Krambeck AE, Handa SE, Lingeman JE. Holmium laser enucleation of the prostate for prostates larger than 175 grams. J Endourol 2010; 24:433-437.
29. Fu WJ, Zhang X, Yang Y, et al. Comparison of 2-micron continuous wave laser vaporesection of the prostate and transurethral resection of the prostate: A prospective nonrandomized trial with 1-year follow-up. Urology 2010; 75:194-199.
30. Chen CH, Chiang PH, Chuang YC, et al. Preliminary results of prostate vaporization in the treatment of benign prostatic hyperplasia by using a 200-W high-intensity diode laser. Urology 2010; 75:658-663.
31. Leonardi R. Preliminary results on selective light vaporization with the sidefiring 980 nm diode laser in benign prostatic hyperplasia: An ejaculation sparing technique. Prostate Cancer Prostatic Dis 2009; 12:277-280.
32. Sun QZ, Guan TY, Qi JG, et al. Histological characteristics of the prostate in men who receive re-TURP for benign prostatic hyperplasia and their clinical significance. Zhong Hua Nan Ke Xue 2010; 16:118-122. The need to repeat a TURP for surgical relief of symptoms secondary to BPH is not inconsequential. The ability to specifically identify individuals at risk for continued growth would significantly impact care and provide insight into patients at greater risk for progression of symptoms as well as a therapy to interrupt the growth process.